Compare ROST & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROST | REGN |
|---|---|---|
| Founded | 1982 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9B | 79.4B |
| IPO Year | 1994 | 1995 |
| Metric | ROST | REGN |
|---|---|---|
| Price | $208.83 | $738.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 24 |
| Target Price | $204.25 | ★ $819.54 |
| AVG Volume (30 Days) | ★ 2.4M | 499.4K |
| Earning Date | 03-03-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.86% | 0.51% |
| EPS Growth | ★ 13.67 | 8.19 |
| EPS | 4.61 | ★ 41.48 |
| Revenue | ★ $21,129,219,000.00 | $5,872,227,000.00 |
| Revenue This Year | $9.43 | $11.69 |
| Revenue Next Year | $6.25 | $10.06 |
| P/E Ratio | $45.15 | ★ $17.95 |
| Revenue Growth | 3.69 | ★ 20.82 |
| 52 Week Low | $122.36 | $476.49 |
| 52 Week High | $216.80 | $821.11 |
| Indicator | ROST | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.24 | 40.83 |
| Support Level | $177.85 | $731.65 |
| Resistance Level | $216.80 | $788.69 |
| Average True Range (ATR) | 4.33 | 19.68 |
| MACD | -0.79 | -4.08 |
| Stochastic Oscillator | 63.95 | 5.12 |
Ross Stores, founded in 1982, is a US-focused off-price apparel and home fashion retailer operating more than 2,100 stores across 43 states, primarily under the Ross Dress for Less banner, with a smaller footprint through DD's Discounts. In fiscal 2024, the company generated over $21 billion in sales. Ross offers branded apparel, footwear, accessories, and home goods at a 20%-60% discount to department and specialty store prices, sourcing closeouts and excess inventory from vendors worldwide.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).